What's in Abramson Cancer Center at Penn Medicine's pipeline?

Abramson Cancer Center at Penn Medicine has 9 drugs in our index: 3 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 3 in Phase 1.

Which companies overlap with Abramson Cancer Center at Penn Medicine's portfolio?

Top competitors by shared drug class: , Eli Lilly, Heather Wakelee, M.D. Anderson Cancer Center, Merck And Co Inc.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/abramson-cancer-center-at-penn-medicine.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Abramson Cancer Center at Penn Medicine — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Abramson Cancer Center at Penn Medicine pipeline: 3 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 1 Phase 3 1 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Prevnar	Prevnar	marketed			Other
Vitamin D3 cholecalciferol)	Vitamin D3 cholecalciferol)	marketed	Vitamin D [EPC]
Vemurafenib (VEM)	Vemurafenib (VEM)	marketed	BRAF inhibitor	BRAF V600E	Oncology
Capecitabine Oral Product	Capecitabine Oral Product	phase 3	Antimetabolite; Fluoropyrimidine	Thymidylate synthase	Oncology

Therapeutic area mix

Other · 3
Oncology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
Eli Lilly · 1 shared drug class
Heather Wakelee · 1 shared drug class
M.D. Anderson Cancer Center · 1 shared drug class
Merck And Co Inc · 1 shared drug class
Mohammed Milhem, MBBS · 1 shared drug class
Qilu Pharmaceutical Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Abramson Cancer Center at Penn Medicine:

Cite this brief

Drug Landscape (2026). Abramson Cancer Center at Penn Medicine — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/abramson-cancer-center-at-penn-medicine. Accessed 2026-05-17.